Follicular lymphoma is a very diverse disease, and decisions to treat in the frontline are made based on histology, disease burden and patient symptoms. The general approach should be a ...

One of the most common forms of Non-Hodgkin's lymphoma is follicular lymphoma, a slow growing blood cancer that affects your immune system. It occurs when infection fighting white cells called B ...

A fusion protein therapy may be an effective treatment option for cutaneous T-cell lymphomas, according to a multicenter clinical trial published in the Journal of Clinical Oncology. Cutaneous T ...

Laurie Adami's experience with CAR T-cell therapy highlights its potential in treating Non-Hodgkin Lymphoma, emphasizing the ...

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

For evaluating response to treatment for follicular lymphoma, computed tomography (CT) has been considered the gold standard, and most clinical studies and trials have used CT as a tool for ...

SAN DIEGO -- The combination of loncastuximab tesirine (Zynlonta) and rituximab achieved promising response rates in patients with relapsed or refractory follicular lymphoma (R/R FL), according to ...

Caimi explained that the findings showed that “1 year of the triplet combination seems to be better than the doublet in patients with relapsed follicular lymphoma.” ...

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

Bristol Myers (BMY) announced the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has ...

Tattoos have been linked as a risk factor to various cancers like skin cancer ... seemed to be highest for diffuse large B-cell Lymphoma and Follicular Lymphoma. Lymphoma is a type of cancer ...